Country | Type | Number | Dated | Case |
Japan | Issued Patent | 7316275 | 07/19/2023 | 2018-057 |
United States Of America | Issued Patent | 11,447,824 | 09/20/2022 | 2018-057 |
United States Of America | Issued Patent | 11,118,224 | 09/14/2021 | 2018-057 |
United States Of America | Issued Patent | 10,253,365 | 04/09/2019 | 2018-057 |
United States Of America | Published Application | 20210388437 | 12/16/2021 | 2018-057 |
European Patent Office | Published Application | 3714050 A0 | 09/30/2020 | 2018-057 |
Rep Of Korea | Published Application | 10-2020-0103638 | 09/02/2020 | 2018-057 |
Class 2 CRISPR–Cas systems (e.g., type V CRISPR/Cas systems
such as Cas12 family systems) are characterized by effector modules that
include a single effector protein. For example, in a type V CRISPR/Cas system,
the effector protein - a CRISPR/Cas endonuclease (e.g., a Cas12a protein) - interacts
with (binds to) a corresponding guide RNA (e.g., a Cas12a guide RNA) to form a
ribonucleoprotein (RNP) complex that is targeted to a particular site in a target
nucleic acid via base pairing between the guide RNA and a target sequence
within the target nucleic acid molecule.
Thus, like CRISPR-Cas9, Cas12 has been harnessed for genome editing
based on its ability to generate targeted, double-stranded DNA (dsDNA) breaks.
UC Berkeley researchers have discovered that RNA-guided DNA
binding unleashes indiscriminate single-stranded DNA (ssDNA) cleavage activity
by Cas12a that completely degrades ssDNA molecules. The researchers found that
target-activated, non-specific ssDNase cleavage is also a property of other
type V CRISPR-Cas12 enzymes. By combining Cas12a ssDNase activation with
isothermal amplification, the researchers were able to achieve attomolar
sensitivity for DNA detection. For
example, rapid and specific detection of human papillomavirus in patient
samples was achieved using these methods and compositions.
Platform for molecular diagnostics for detecting target DNAs
(double or single stranded)
Cas12, Cpf1, CRISPR, genome editing